Fasinumab growth trends

On September 20, 2016, Regeneron (REGN) entered into a partnership with Teva Pharmaceutical (TEVA) for the development and commercialization of fasinumab in the US. Regeneron has already collaborated with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of this drug in Korea, Japan, and nine other Asian countries, with the exception of China.

The chart below gives a snapshot of Regeneron’s research pipeline across various development stages. At the end of 2Q17, Regeneron (REGN) had six approved drugs and 17 investigational products in its portfolio. fasinumab, a Nerve Growth Factor antibody for pain, is one of the products in Regeneron’s late-stage research pipeline.

Regeneron Is Focused on Advancing Development of Fasinumab for Chronic Pain

Market opportunity

Nonsteroidal Antiinflammatory Drugs (or NSAIDs), when used for chronic pain in elderly patients, may result in adverse cardiovascular and gastrointestinal side effects. On the other hand, opioids have demonstrated low efficacy in managing chronic pain in osteoarthritis patients. Many patients are unable to tolerate opioids, which are highly addictive and have significant potential of being abused by patients.

In this context, non-opioid therapy, fasinumab, may help control chronic pain through an innovative mechanism of action. Currently, the safety and efficacy of this investigational therapy are being studied in a Phase 3 trial for patients suffering from osteoarthritis of the knee or hip.

In 2H17, Regeneron also expects to commence a Phase 3 trial to study the potential of fasinumab in chronic back pain indication. fasinumab could enable Regeneron to compete effectively with other pain segment players such as The Medicines Company (MDCO) and Endo Pharmaceuticals (ENDP).

While the drug has already demonstrated its ability to reduce pain in Phase 2 trials, Regeneron and Teva Pharmaceutical would have to generate a large amount of safety data for fasinumab due to known safety concerns for this class of drugs.

If the efficacy and safety data support fasinumab’s regulatory approval, it may have a favorable impact on Regeneron stock and the Vanguard Health Care ETF (VHT). Regeneron makes up about 1.0% of VHT’s total portfolio holdings.

Latest articles

Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant's fiscal 2019 second-quarter earnings release. It missed analysts' revenue estimate and cut its fiscal 2019 revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.

The SPDR Gold Shares ETF (GLD), which tracks physical gold prices, has underperformed the broader markets year-to-date, rising just 4.4% compared to the S&P 500’s (SPY) gain of 15.9% as of June 14. The sentiment for gold, however, has been turning around.

Safe havens such as Treasuries and gold were back in favor on June 14 as stocks fell due to rising tensions in the Middle East, concerns over growth, and the looming threat of the US-China trade war. The tech-heavy Nasdaq Composite Index fell 0.67% in the first hour of trading.

Lululemon (LULU) stock rose 2.1% on June 13 in reaction to better-than-expected first-quarter results and an upgraded outlook for fiscal 2019 overall. The company's first-quarter adjusted EPS grew 34.5% to $0.74 on revenue growth of 20.4% to $782.32 million. Analysts had expected EPS of $0.70 and revenue of $755.31 million. Here's why the outlook got an upgrade.

14 Jun

IEA Again Slashes Its Oil Demand Growth Estimate

WRITTEN BY Rabindra Samanta

As of 4:40 AM Eastern Time today, US crude oil active futures were at $51.83, ~4% below their closing level in the previous week. If US crude oil prices stay at those levels today, they'll mark their third week of decline in five weeks.

Amazon is discontinuing its Amazon Restaurants service, which has been delivering food for restaurants in parts of the United States. Amazon Restaurants launched in the United States in 2015 and entered the British market the following year. However, it met strong opposition in the British market.